Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0915 Marinus CDD
BioCentury & Getty Images

Product Development

Buoyed by Phase III data, Marinus aims for first NDA in a rare seizure disorder

Sep 15, 2020 | 9:30 PM GMT

A Phase III readout that boosted Marinus’ value on Tuesday is the first in a series of upcoming milestones that could lead to the company carving out a commercial niche in rare seizure disorders.

Trial results released

Read the full 648 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers